Free Trial
NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

IN8bio logo
$2.35 -0.04 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$2.32 -0.03 (-1.45%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IN8bio Stock (NASDAQ:INAB)

Advanced

Key Stats

Today's Range
$2.33
$2.43
50-Day Range
$1.91
$2.40
52-Week Range
$1.91
$16.70
Volume
52,182 shs
Average Volume
79,368 shs
Market Capitalization
$10.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$180.00
Consensus Rating
Hold

Company Overview

IN8bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

INAB MarketRank™: 

IN8bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 654th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IN8bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    IN8bio has a consensus price target of $180.00, representing about 7,559.6% upside from its current price of $2.35.

  • Amount of Analyst Coverage

    IN8bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about IN8bio's stock forecast and price target.
  • Earnings Growth

    Earnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IN8bio is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IN8bio is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IN8bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about IN8bio's valuation and earnings.
  • Percentage of Shares Shorted

    1.62% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently increased by 42.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IN8bio does not currently pay a dividend.

  • Dividend Growth

    IN8bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.62% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently increased by 42.48%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 3 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IN8bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of IN8bio is held by insiders.

  • Percentage Held by Institutions

    92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IN8bio's insider trading history.
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INAB Stock News Headlines

In8bio, Inc. Reports Improved Financial Performance
IN8bio (INAB) Q2 Loss Narrows 77%
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
See More Headlines

INAB Stock Analysis - Frequently Asked Questions

IN8bio's stock was trading at $7.7160 on January 1st, 2025. Since then, INAB stock has decreased by 69.5% and is now trading at $2.35.

IN8bio, Inc. (NASDAQ:INAB) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.26.

IN8bio shares reverse split on Friday, June 6th 2025.The 1-30 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

IN8bio (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2025
Today
10/06/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INAB
CIK
1740279
Fax
N/A
Employees
20
Year Founded
2016

Price Target and Rating

High Price Target
$180.00
Low Price Target
$180.00
Potential Upside/Downside
+7,447.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($9.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-184.97%
Return on Assets
-126.75%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
7.03
Quick Ratio
7.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.00 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
4,540,000
Free Float
4,109,000
Market Cap
$10.83 million
Optionable
Not Optionable
Beta
0.03

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INAB) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners